drugset / Trial / NCT01368757
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Phase 1/2
Unknown
30 enrolled
Study Group of Medical Tumour Therapy (AGMT)
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started once an optimal dose has been found. The primary endpoint will concern the efficacy of lenalidomide in patients with CMML according to the WHO diagnostic criteria.
Timeline
- Start
- 2010-06
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |